Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aponermin + pomalidomide + dexamethasone for relapsed or refractory multiple myeloma
ChiCTR2400092626Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aponermin, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Henan Cancer Hospital. Primary endpoint: Overall response rate after 4 courses of treatment. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
aponerminpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400092626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092626.